NuVasive (NASDAQ:NUVA) and STRATA Skin Sciences (NASDAQ:SSKN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.
Volatility & Risk
NuVasive has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Insider and Institutional Ownership
26.9% of STRATA Skin Sciences shares are held by institutional investors. 1.0% of NuVasive shares are held by company insiders. Comparatively, 45.6% of STRATA Skin Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares NuVasive and STRATA Skin Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|STRATA Skin Sciences||-18.33%||-18.83%||-12.24%|
Earnings and Valuation
This table compares NuVasive and STRATA Skin Sciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NuVasive||$1.03 billion||2.89||$83.00 million||$1.91||30.28|
|STRATA Skin Sciences||$31.45 million||2.92||-$18.83 million||$1.97||1.56|
NuVasive has higher revenue and earnings than STRATA Skin Sciences. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations for NuVasive and STRATA Skin Sciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|STRATA Skin Sciences||0||0||3||0||3.00|
NuVasive presently has a consensus target price of $64.35, indicating a potential upside of 11.28%. STRATA Skin Sciences has a consensus target price of $6.00, indicating a potential upside of 95.44%. Given STRATA Skin Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe STRATA Skin Sciences is more favorable than NuVasive.
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.